Bacterial Lipopolysaccharide as Adjuvants

Arenas, Jesús

doi:10.1007/978-3-319-00978-0_7

Search citation statements

Order By: Relevance

Paper Sections

Select...

Modulation By Drugs1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2014

2017

Publication Types

Select...

Book1

Article1

Relationship

Self Cite1

Independent1

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This has inspired researchers to generate diverse LPS-based species (i.e., Lipid A) with reduced toxicity but with immunomodulator properties. Some were proposed as immunomodulators due to their activation of hTLR4 signaling while exhibiting acceptable toxicity (Arenas 2014). In vaccine technology, their use is extremely valuable, since they can be used to promote the immunogenicity of specific vaccines.…”

Section: Modulation By Drugsmentioning

confidence: 99%

Bacterial Lipopolysaccharide

Arenas¹

2014

Encyclopedia of Inflammatory Diseases

Self Cite

View full text Add to dashboard Cite

Section: Modulation By Drugsmentioning

confidence: 99%

Bacterial Lipopolysaccharide

Arenas¹

2014

Encyclopedia of Inflammatory Diseases

Self Cite

View full text Add to dashboard Cite

A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

Manzo

Cutignano

Pagano

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Dendritic Cells (DCs) recognize infectious non-self molecules and engage the adaptive immune system thereby initiating long lasting, antigen-specific responses. As such, the ability to activate DCs is considered a key tool to enhance the efficacy and quality of vaccination. Here we report a novel immunomodulatory sulfolipid named β-SQDG18 that prototypes a class of natural-derived glycolipids able to prime human DCs by a TLR2/TLR4-independent mechanism and trigger an efficient immune response in vivo. β-SQDG18 induces maturation of DC with the upregulation of MHC II molecules and co-stimulatory proteins (CD83, CD86), as well as pro-inflammatory cytokines (IL-12 and INF-γ). Mice immunized with OVA associated to β-SQDG18 (1:500) produced a titer of anti-OVA Ig comparable to traditional adjuvants. In an experimental model of melanoma, vaccination of C57BL/6 mice with β-SQDG18-adjuvanted hgp10 peptide elicited a protective response with a reduction in tumour growth and increase in survival.

show abstract

Bacterial Lipopolysaccharide as Adjuvants

Cited by 2 publications

References 78 publications

Bacterial Lipopolysaccharide

Bacterial Lipopolysaccharide

A new marine-derived sulfoglycolipid triggers dendritic cell activation and immune adjuvant response

Contact Info

Product

Resources

About